Boston, MA 06/05/2013 (wallstreetpr) – The share prices of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) had declined by 18.10 percent to close at $3.71 per share. The shares of the company had been trading in the range of $3.56 to $4.04 per share during the day. With this continuous decline in share prices, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) had plunged to new lows with the 52 week low price level of the company recorded at $3.56 per share and the 52 week high price level of the company is at $11.44 per share.
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) is involved in the development and commercialization of drugs for the treatment of muscular disorders, inflammatory diseases and autoimmune diseases. The clinical stage drug development company conducts various researches for the development of drugs and treatment therapies with special focus on intracellular signaling pathways and other related targets which are highly critical to disease mechanisms.
The shares of the clinical stage drug development company, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) had been declining in prices at heavy trading volumes in the recent days. Such volumes and combining decline in share prices had led the company to slide to new bottoms with the recent low being $3.56 per share.
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) had witnessed a trading volume of 6.01 million shares on the trading session of Tuesday, while the average trading volume for the company is at 800,857 shares per day. The company presently holds 87.14 million shares outstanding in the market with an institutional ownership of 94 percent of its holdings.
